Cytokine and chemokine expression kinetics after corneal transplantation

被引:71
作者
King, WJ
Comer, RM
Hudde, T
Larkin, DFP
George, AJT
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Immunol, London W12 0NN, England
[2] Moorfields Eye Hosp, London, England
关键词
D O I
10.1097/00007890-200010270-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Allogeneic rejection is the most common cause of corneal graft failure. The aim of this work was to establish the kinetics of cytokine and chemokine mRNA expression before and after onset of corneal graft rejection. Methods. Intracorneal cytokine and chemokine mRNA levels were investigated in the Brown Norway-->Lewis inbred rat model in which rejection onset is observed at 8/9 days after grafting in all animals. Nongrafted corneas and syngeneic (Lewis-->Lewis) corneal transplants were used as controls. Donor and recipient cornea was examined by quantitative competitive reverse transcription-polymerase chain reaction (RT-PCR) for hypoxyanthine phosphoribosyltransferase (HPRT), CD3, CD25, interleukin (IL)-1 beta, IL-1RA, IL-2, IL-6, IL-10, interferon-gamma (IFN-gamma), tumor necrosis factor (TNF), transforming growth factor (TGF)-beta1, and macrophage inflammatory protein (MIP)-II and by nonquantitative RT-PCR for IL-4, IL-5, IL-12 p40, IL-13, TGF-beta2, monocyte chemotactic protein-1 (MCP-1), MIP-1 alpha, MIP-1 beta, and RANTES (for regulated upon activation normal T cell expressed and secreted), Results. A biphasic expression of cytokine and chemokine mRNA was found after transplantation. During the early phase (days 3-9), there was an elevation of the majority of the cytokines examined, including IL-1 beta, IL-6, IL-10, IL-12 p40, and MIP-II. There was no difference in cytokine expression patterns between allogeneic or syngeneic recipients at this time. In syngeneic recipients, cytokine levels reduced to pretransplant levels by day 13, whereas levels of all cytokines rose after observed rejection onset in the allografts, including TGF-beta1, TGF-beta2, and IL-1RA. The T cell-derived cytokines IL-4, IL-13, and IFN-gamma were detected only during the rejection phase in allogeneic recipients. Conclusions. There is an early cytokine and chemokine response to the transplantation process, evident in syngeneic and allogeneic grafts, that probably drives angiogenesis, leukocyte recruitment, and affects leukocyte functions. After an immune response has been generated, allogeneic rejection results in the expression of Th1 cytokines (IL-2, IL-12 p40, IFN-gamma), Th2 cytokines (IL-4, IL-6, IL-10, and IL-13), and anti-inflammatory/Th3 cytokines (TGF-beta1/2 and IL-1RA).
引用
收藏
页码:1225 / 1233
页数:9
相关论文
共 46 条
[1]   Lipoadenofection-mediated gene delivery to the corneal endothelium:: Prospects for modulating graft rejection [J].
Arancibia-Cárcamo, CV ;
Oral, HB ;
Haskard, DO ;
Larkin, DFP ;
George, AJT .
TRANSPLANTATION, 1998, 65 (01) :62-67
[2]  
ASBELL PA, 1994, INVEST OPHTH VIS SCI, V35, P1293
[3]   PROLONGATION OF RAT CORNEAL GRAFT-SURVIVAL BY TREATMENT WITH ANTI-CD4 MONOCLONAL-ANTIBODY [J].
AYLIFFE, W ;
ALAM, Y ;
BELL, EB ;
MCLEOD, D ;
HUTCHINSON, IV .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1992, 76 (10) :602-606
[4]   LIMITATIONS AND MODIFICATIONS OF QUANTITATIVE POLYMERASE CHAIN-REACTION - APPLICATION TO MEASUREMENT OF MULTIPLE MESSENGER-RNAS PRESENT IN SMALL AMOUNTS OF SAMPLE RNA [J].
BABU, JS ;
KANANGAT, S ;
ROUSE, BT .
JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 165 (02) :207-216
[5]  
BOUABOULA M, 1992, J BIOL CHEM, V267, P21830
[6]  
CUBITT CL, 1993, INVEST OPHTH VIS SCI, V34, P3199
[7]  
D'Orazio TJ, 1998, J IMMUNOL, V160, P2089
[8]   CYTOKINE GENE-TRANSCRIPTION IN VASCULARIZED ORGAN GRAFTS - ANALYSIS USING SEMIQUANTITATIVE POLYMERASE CHAIN-REACTION [J].
DALLMAN, MJ ;
LARSEN, CP ;
MORRIS, PJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (02) :493-496
[9]   Topical interleukin 1 receptor antagonist promotes corneal transplant survival [J].
Dana, MR ;
Yamada, J ;
Streilein, JW .
TRANSPLANTATION, 1997, 63 (10) :1501-1507
[10]  
Dana MR, 1998, INVEST OPHTH VIS SCI, V39, P70